Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir - ViiV Healthcare

Next Previous
Drug Profile

Dolutegravir - ViiV Healthcare

Alternative Names: '572; 1349572; Dolutegravir sodium; DTG; GSK-1349572; S-349572; S/GSK 1349572; Tivicay; Tivicay PD

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi-GlaxoSmithKline Pharmaceuticals
  • Developer Bellvitge University Hospital; GSK; INSERM; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA); PENTA Foundation; Shionogi-GlaxoSmithKline Pharmaceuticals; University of Liverpool; Viatris; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Oxazines; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase III HIV infections

Most Recent Events

  • 28 Nov 2025 No recent reports of development identified for phase-I development in HIV-1-infections(In infants, In neonates, Prevention) in USA (PO, Fast dissolve)
  • 28 Nov 2025 No recent reports of development identified for phase-I development in HIV-1-infections(In infants, In neonates, Prevention) in USA (PO, Suspension)
  • 09 Mar 2025 Adverse events and pharmacokinetics data from a phase I trial in HIV infections presented at the 32nd Conference on Retroviruses and Opportunistic Infections 2025 (CROI-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top